Literature DB >> 20949240

Assessment of the oxidative stress markers in patients with chronic renal insufficiency undergoing dialysis treatment.

S Coaccioli1, M L Standoli, R Biondi, A Panaccione, P Landucci, R Del Giorno, A Paladini, M Standoli, A Puxeddu.   

Abstract

AIMS: Uraemia is a disease characterised by a significant oxidative stress, and it is a wide agreement that oxidative stress which accompanies uraemia, increases the inflammatory state and promotes the alterations of tiny molecules such as amino acids, proteins, lipids, and carbohydrates. There are numerous records of how ROS are connected to the pathology of end stage renal disease (ESRD). The aim of this study is to assess the Total Antioxidant Capacity (TAC), the Thiolic Capacity (TC) and the Pro-Oxidant Capacity (POC) in the serum of patients undergoing dialysis treatment.
MATERIALS AND METHODS: Forthy-six patients have been recruited (32 men, 14 women; mean age 68.5±15.8) who received hemodialytic treatment triweekly. Three methods have been used: oxy adsorbent test (mmol/l) to determine TAC values; d-ROM test (mg/100 mg/H₂O₂) to determine POC; SHp-test (mmol/l) to determine TC.
RESULTS: In patients who underwent hemodialysis, TAC levels were: pre-dialysis, 265.9±30.5; post-dialysis, 300.0±40.6; TC levels: pre-dialysis, 267.4±59.1; post-dialysis, 303.2±116.7; POC levels: predialysis, 86.2±16.9; post-dialysis, 98.6±17.0; NS: TAC, 335.6±46.3; TC, 434.0±22.2; POC, 56.3±7.4. TAC in both pre- and post-dialysis is reduced compared to the NS (p < 0.05); moreover TAC increases after dialysis (p < 0.05). Pre- and post-dialysis TC is reduced compared to NS (p < 0.05); available TC increases after dialysis, although not statistically significant. Pre- and post-dialysis POC in patients undergoing dialysis is increased compared to the NS (p < 0.05); moreover, POC tends to increase after dialysis ( p < 0.05). The data obtained from our study also show that the TAC is reduced in the patients subjected to hemodialysis compared to the NS, both before and after dialysis treatment; TAC increased after dialysis, even though it did not reach the level of the control group.
CONCLUSION: Our study has demonstrated that exists a profound imbalance between antioxidants and the production of ROS in ESRD patients, which determines oxidative stress and eventually leads to atherosclerosis and cardiovascular complications. This, in turn, represents the major cause of morbidity and mortality in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20949240

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  5 in total

1.  Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.

Authors:  Arata Nakajima; Yasuchika Aoki; Masato Sonobe; Hiroshi Takahashi; Masahiko Saito; Koichi Nakagawa
Journal:  Clin Rheumatol       Date:  2016-11-17       Impact factor: 2.980

2.  Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.

Authors:  Mariko Noguchi-Sasaki; Yusuke Sasaki; Yukari Matsuo-Tezuka; Hideyuki Yasuno; Mitsue Kurasawa; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2016-01-06       Impact factor: 2.490

3.  Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients.

Authors:  Esther G Gerrits; Helen L Lutgers; Gertie H W Smeets; Klaas H Groenier; Andries J Smit; Reinold O B Gans; Henk J G Bilo
Journal:  Nephron Extra       Date:  2012-07-04

4.  Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.

Authors:  Arata Nakajima; Keiichiro Terayama; Masato Sonobe; Yorikazu Akatsu; Junya Saito; Masaki Norimoto; Shinji Taniguchi; Ayako Kubota; Yasuchika Aoki; Koichi Nakagawa
Journal:  Cureus       Date:  2021-11-19

5.  Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis.

Authors:  Arata Nakajima; Keiichiro Terayama; Masato Sonobe; Yasuchika Aoki; Hiroshi Takahashi; Yorikazu Akatsu; Junya Saito; Shinji Taniguchi; Manabu Yamada; Ayako Kubota; Koichi Nakagawa
Journal:  BMC Rheumatol       Date:  2019-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.